Blockage of spinal endothelin A receptors attenuates bone cancer pain via regulating Akt/ERK signaling pathway in mice
Bone cancer pain (BCP) is a common source of pain in patients with advanced stage and metastatic cancer; however, existing treatment for this kind of pain remains deficient. Being closely related to sensory change and inflammatory pain in both the central and peripheral nervous systems, endothelin A receptor (ETAR) plays an essential role in pain processing. As a result, ETAR antagonist has been reported to alleviate both neuropathic and inflammatory pain. Thus far, the role of ETAR in the process of BCP is still ambiguous. (Source: Neuropeptides)
Source: Neuropeptides - January 23, 2018 Category: Neuroscience Authors: Ming-Ming Han, Cheng-Wei Yang, Chi-Wai Cheung, Juan Li Source Type: research
Antinociceptive profiles and mechanisms of centrally administered oxyntomodulin in various mouse pain models
In the present study, the antinociceptive profiles of oxyntomodulin were examined in ICR mice. Oxyntomodulin administered intrathecally (i.t.) and intracerebroventricularly (i.c.v.) (from 1 to 5 μg/5μl) showed an antinociceptive effect in a dose-dependent manner as measured in the acetic acid-induced writhing test. Moreover, cumulative response time of nociceptive behaviors induced by intraplantar formalin injection was reduced by i.t. or i.c.v. treatment with oxyntomodulin during the sec ond, but not the first phase. (Source: Neuropeptides)
Source: Neuropeptides - January 21, 2018 Category: Neuroscience Authors: Soo-Hyun Park, Jae-Ryeong Lee, Sang-Pil Jang, Seyung-Hwan Park, Hee-Jung Lee, Jung-Woo Hong, Hong-Won Suh Source Type: research
Apelin-13 ameliorates cognitive impairments in 6-hydroxydopamine-induced substantia nigra lesion in rats
In this study the effects of apelin-13 were investigated on cognitive disorders in rat Parkinsonism experimental model. 6-hydroxydopamine (6-OHDA) was administrated into the substantia nigra. (Source: Neuropeptides)
Source: Neuropeptides - January 5, 2018 Category: Neuroscience Authors: Elham Haghparast, Saeed Esmaeili-Mahani, Mehdi Abbasnejad, Vahid Sheibani Source Type: research
Apelin-13 ameliorates cognitive impairments in 6-hydroxy dopamine-induced substantia nigra lesion in rats
In this study the effects of apelin-13 were investigated on cognitive disorders in rat Parkinsonism experimental model. 6-hydroxydopamine (6-OHDA) was administrated into the substantia nigra. (Source: Neuropeptides)
Source: Neuropeptides - January 5, 2018 Category: Neuroscience Authors: Elham Haghparast, Saeed Esmaeili-Mahani, Mehdi Abbasnejad, Vahid Sheibani Source Type: research
Oxaliplatin-induced changes in expression of transient receptor potential channels in the dorsal root ganglion as a neuropathic mechanism for cold hypersensitivity
Transient receptor potential (TRP) receptors are involved in the development of chemotherapy-induced peripheral neuropathic pain, which is a common side effect of selected chemotherapeutic agents such as oxaliplatin. However, the precise contribution of TRPs to this condition remains unknown. Cold hypersensitivity is the hallmark of oxaliplatin-induced neuropathy, so we used a preclinical model of oxaliplatin-induced cold hypersensitivity in rats to determine the effects of oxaliplatin on TRP channels. (Source: Neuropeptides)
Source: Neuropeptides - December 15, 2017 Category: Neuroscience Authors: Akiko Chukyo, Terumasa Chiba, Toshie Kambe, Ken Yamamoto, Kazuyoshi Kawakami, Kyoji Taguchi, Kenji Abe Source Type: research
Blocking constitutive activity of GHSR1a in the lateral amygdala facilitates acquisition of conditioned taste aversion
Ghrelin is a circulating peptide hormone promoting feeding and regulating energy metabolism in human and rodents. Ghrelin functions by binding to its receptor, the growth hormone secretagogue receptor 1a (GHSR1a), which are widely distributed throughout the brain including the amygdala, a brain region important for regulating valenced behavior, such as aversion. Interestingly, GHSR1a was once characterized by highly constitutive, ligand-independent activity. However, the physiological importance of such ligand-independent signaling on aversive memory processing has not been tested yet. (Source: Neuropeptides)
Source: Neuropeptides - December 5, 2017 Category: Neuroscience Authors: Nan Li, Ge Song, Yaohui Wang, Qianqian Zhu, Fubing Han, Chonghui Zhang, Yu Zhou Source Type: research
A β oligomer eliminating compounds interfere successfully with pEAβ(3–42) induced motor neurodegenerative phenotype in transgenic mice
Currently, there are no causative or disease modifying treatments available for Alzheimer's disease (AD). Previously, it has been shown that D3, a small, fully d-enantiomeric peptide is able to eliminate low molecular weight A β oligomers in vitro, enhance cognition and reduce plaque load in AD transgenic mice. To further characterise the therapeutic potential of D3 towards N-terminally truncated and pyroglutamated Aβ (pEAβ(3–42)) we tested D3 and its head-to-tail tandem derivative D3D3 both in vitro and in vivo in t he new mouse model TBA2.1. (Source: Neuropeptides)
Source: Neuropeptides - November 27, 2017 Category: Neuroscience Authors: Tina Dunkelmann, Kerstin Teichmann, Tamar Ziehm, Sarah Schemmert, Daniel Frenzel, Markus Tusche, Christina Dammers, Dagmar J ürgens, Karl-Josef Langen, Hans-Ulrich Demuth, Nadim Jon Shah, Janine Kutzsche, Antje Willuweit, Dieter Willbold Source Type: research
A β oligomer eliminating compounds interfere successfully with pEAβ (3–42) induced motor neurodegenerative phenotype in transgenic mice
Currently, there are no causative or disease modifying treatments available for Alzheimer's disease (AD). Previously, it has been shown that D3, a small, fully d-enantiomeric peptide is able to eliminate low molecular weight A β oligomers in vitro, enhance cognition and reduce plaque load in AD transgenic mice. To further characterise the therapeutic potential of D3 towards N-terminally truncated and pyroglutamated Aβ (pEAβ(3–42)) we tested D3 and its head-to-tail tandem derivative D3D3 both in vitro and in vivo in t he new mouse model TBA2.1. (Source: Neuropeptides)
Source: Neuropeptides - November 27, 2017 Category: Neuroscience Authors: Tina Dunkelmann, Kerstin Teichmann, Tamar Ziehm, Sarah Schemmert, Daniel Frenzel, Markus Tusche, Christina Dammers, Dagmar J ürgens, Karl-Josef Langen, Hans-Ulrich Demuth, Nadim Jon Shah, Janine Kutzsche, Antje Willuweit, Dieter Willbold Source Type: research
Peptides isolated from animal venom as a platform for new therapeutics for the treatment of Alzheimer's disease
Alzheimer's disease (AD) is a progressive neurodegenerative disease that deeply affects patients, their family and society. Although scientists have made intense efforts in seeking the cure for AD, no drug available today is able to stop AD progression. In this context, compounds isolated from animal venom are potentially successful drugs for neuroprotection, since they selectively bind to nervous system targets. In this review, we presented different studies using peptides isolated from animal venom for the treatment of AD. (Source: Neuropeptides)
Source: Neuropeptides - November 27, 2017 Category: Neuroscience Authors: L.C. Camargo, G.A.A. Campos, P.R. Galante, A.M. Biolchi, J.C. Gon çalves, K.S. Lopes, M.R. Mortari Tags: News and reviews Source Type: research
Combined gastrin releasing peptide-29 and glucagon like peptide-1 reduce body weight more than each individual peptide in diet-induced obese male rats
To test the hypothesis that gastrin releasing peptide-29 (GRP-29) combined with glucagon like peptide-1 (7 –36) (GLP-1 (7–36)) reduce body weight (BW) more than each of the peptides given individually, we infused the two peptides (0.5nmol/kg each) in the aorta of free feeding, diet-induced obese (DIO) male Sprague Dawley rats once daily for 25days and measured BW. We found that GRP-29 and GLP-1 reduc e BW, GRP-29 reduced it more than GLP-1 and GRP-29+GLP-1 reduce BW more than each peptide given alone. (Source: Neuropeptides)
Source: Neuropeptides - November 20, 2017 Category: Neuroscience Authors: Thaer R. Mhalhal, Martha C. Washington, Kayla D. Newman, John C. Heath, Ayman I. Sayegh Source Type: research
Neuroinflammation induced by amyloid β25–35 modifies mucin-type O-glycosylation in the rat's hippocampus
Amyloid- β (Aβ) plays a relevant role in the neurodegenerative process of Alzheimer's disease (AD). The 25–35 peptide of amyloid-β (Aβ25–35) induces the inflammatory response in brain experimental models. Mucin-type O-glycosylation has been associated with inflammation of brain tissues in AD, thus in this work, we aimed at identifying changes in the glycosylation profile generated by the injection of Aβ25–35 into the CA1 of the hippocampus of rats, using histochemistry with lectins. Our results indicate that 100μM Aβ25–35 induce increased recognition of the Amaranthus leucocarpus lectin (ALL) (specific for G...
Source: Neuropeptides - November 20, 2017 Category: Neuroscience Authors: Ivan Ramos-Martinez, Pamela Mart ínez-Loustalot, Liliana Lozano, Tarik Issad, Daniel Limón, Alfonso Díaz, Armando Perez-Torres, Jorge Guevara, Edgar Zenteno Source Type: research
Ghrelin protects retinal ganglion cells against rotenone via inhibiting apoptosis, restoring mitochondrial function, and activating AKT-mTOR signaling
Ghrelin, a 28-amino acid peptide hormone, has protective effects on neuronal cells. The present study aimed to examine the neuroprotective effects of ghrelin on the rat retinal ganglion cells in the rotenone-induced in vitro model of Parkinson's disease (PD). Cell viability and cell apoptosis were determined by MTT assay and flow cytometry, respectively. Mitochondrial functions were detected by mitochondrial complex I activity assay and mitochondrial membrane potential (MMP) assay. The mRNA and protein expression levels were determined by qRT-PCR and western blot, respectively. (Source: Neuropeptides)
Source: Neuropeptides - November 20, 2017 Category: Neuroscience Authors: Shenwen Liu, Sheng Chen, Jing Ren, Baijun Li, Bo Qin Source Type: research
